-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 30, Renfu Medicine issued an announcement stating that recently, its subsidiary Hubei Biomedical Industry Technology Research Institute Co.
, Ltd.
(referred to as the "Research Institute Co.
, Ltd.
", the company holds 50.
24% of its shares), Wuhan Renfu Kangyao Industry Co.
, Ltd.
(referred to as "Ren Fuli Kang", the company holds 67.
33% of its equity, and according to the forward repurchase agreement of the capital increase agreement, the company holds 100% of its equity) received the HW021199 film approved and issued by the State Drug Administration "Notice of Approval of Drug Clinical Trials"
.
HW021199 tablets are suitable for the treatment of idiopathic pulmonary fibrosis
.
At present, there is no drug with the same target on the market globally.
According to IQVIA statistics, the global sales of nintedanib and pirfenidone in 2019 were approximately US$980 million and US$747 million, respectively
.
Research Institute Co.